|
| Antigen targeted | Immunotoxin characteristics | Clinical trial | Tumor treated | Outcome | References |
|
| TR: Tf-CRM107 | A conjugate of human TR and full-length DT with two point mutations in the B chain with reduced toxin binding (CRM107) | Phase I/II | 44 patients (recurrent GBM or AA) | Median survival 37 weeks; 5/34 CR; 7/34 PR | [38, 39] |
| TR: 454A12-rRA | A conjugate of a mAb (454A12) to the human TR and rRA | Phase I | Eight leptomeningeal neoplasia patients | Tumor progression | [40] |
| IL-4R: IL-4(38-37)-PE38KDEL (NBI-3001) | A circularly permuted recombinant IL-4 fused to PE | Phase I/II | 31 patients (25 GBM and 6 AA) | Median survival 8.2 months; 6 month survival 52% | [41–44] |
| IL-13R: IL-13-PE38QQR (Cintredekin Besudotox) | A chimeric toxin composed of hIL-13 and a mutated version of PE | Phase I/II/III | Phase II: 51 patients (46 GBM, 3 AA, 1 anaplastic oligoastrocytoma, 1 AO; Phase III: 296 patients (276 GBM confirmed) | Phase II: median survival 45.9 weeks Phase III: IL13-PE38QQR compared to GW: Median survival 36.4 weeks for the IL13-PE38QQR group and 35.3 weeks for the GW group | [45, 46] |
| EGFR: TP-38 (IVAX) | A chimeric toxin composed of EGFR ligand TGF-α and PE | Phase I | Twenty patients [17 GBM, 1 GSC, 1 metastatic spindle cell sarcoma, 1 AO] | Median survival 28 weeks | [47–49] |
| Mutant EGFRvIII: MR1-1-PE38KDEL | An affinity-matured scFv specific for EGFRvIII, MR1-1 fused to PE | Phase I | Ongoing | | |
|
